Monograph
C03AA01 - Bendroflumethiazide |
Propably not porphyrinogenic |
PNP |
Rationale
Sulfonamide type of drug. Clinical experience points, however, to non-porphyrinogenicity.
Chemical description
sulfonamide type of drug.
Therapeutic characteristics
Thiazide diuretic and antihypertensive.
Metabolism and pharmacokinetics
More specific data on metabolism are lacking. No observations of CYP interaction. Mainly eliminated via non-renal mechanisms, only 30 % excreted in unchanged form in urine.
Personal communication
Thunell, patient report tolerated (n=1). Andersson, patient report (n=11): tolerated.
IPNet drug reports
Uneventful use reported in 37 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Aprinox · Aprinox 2.5mg tablets · Aprinox 5mg tablets · Bendroflumethiazide · Bendroflumethiazide 1.25mg/5ml oral suspension · Bendroflumethiazide 1mg/5ml oral suspension · Bendroflumethiazide 2.5mg tablets · Bendroflumethiazide 2.5mg/5ml oral suspension · Bendroflumethiazide 2mg/5ml oral solution · Bendroflumethiazide 2mg/5ml oral suspension · Bendroflumethiazide 3.75mg/5ml oral solution · Bendroflumethiazide 3.75mg/5ml oral suspension · Bendroflumethiazide 5mg tablets · Bendroflumethiazide 5mg/5ml oral suspension · Neo-Naclex · Neo-Naclex 2.5mg tablets · Neo-Naclex 5mg tablets · Urizide · Urizide 2.5mg tablets · Urizide 5mg tabletsNorway
Bendroflumethiazide wockhardt
© NAPOS 2024